This news is covered by the Medical Dialogues Bureau present at the TCT Conference 2025, being held in San Francisco, USA.

Results from the first randomized clinical trial in the United States to compare a sirolimus-eluting balloon (DEB) to a ...

An Indian-made heart stent, Supraflex Cruz, has demonstrated a lower failure rate in high-risk patients compared to a US-made market leader. The TUXEDO-2 trial, conducted in India, showed the Indian ...

An Indian medical innovation has achieved a major global recognition with a new generation heart stent manufactured in India ...

The intracoronary fibrinolysis infusion joins a host of other failed treatments to improve microvascular obstruction after ...

This news was covered by the Medical Dialogues Bureau, which was present at the TCT Conference 2025 held in San Francisco, ...

Sahajanand Medical Technologies (SMT) announced significant new findings from four landmark clinical studies, namely TUXEDO ...

SMT’s Supraflex Cruz shows consistent and robust clinical outcomes: Our Bureau, Mumbai Wednesday, October 29, 2025, 16:15 Hrs [IST] Sahajanand Medical Technologies (SMT), a medi ...

After percutaneous coronary intervention (PCI), dual antiplatelet therapy (DAPT) is recommended for 6 months in stable coronary artery disease1,2 and 12 months in acute coronary syndromes.3,4 Over the ...

In a randomized trial of patients with a previous myocardial infarction and with residual inflammation, a monoclonal antibody targeting the LOX-1 receptor, thought to contribute to atherosclerotic ...